T

Thermo Fisher Scientific

Makes lab instruments, reagents and supplies

Regulatory Program Manager - FSP client dedicated

Full-TimeUpdated
No salary listed
Senior
Bachelor's, Master's, PharmD, PhD
North Carolina, USA
RemoteFully remote; workplace scope is North Carolina, USA.
Project & Program ManagementProgram Management

About the job

Requirements
  • A BA/BS degree in a scientific, engineering, or healthcare discipline is required.
  • At least 7 years of progressive experience in the pharmaceutical, biotechnology, or related life sciences industry, including at least 5 years in regulatory or regulatory program management.
  • Ability to partner on regulatory strategy and lead execution across all stages of product development, including IND/BLA/MAA submissions, global registration, and post-marketing activities.
  • Deep understanding of U.S. regulatory requirements and working knowledge of international regulations and agency expectations.
  • Demonstrated success managing complex regulatory deliverables across cross-functional teams in a matrixed organization while maintaining alignment with strategic priorities.
  • Hands-on experience with eCTD and a strong command of regulatory documentation, formatting, and submission strategy.
  • Exceptional communication and influencing skills, including the ability to synthesize complex regulatory information and communicate clear recommendations to senior leadership and global stakeholders.
  • Strong judgment and agility in managing competing priorities, resource constraints, and evolving program needs.
  • Ability to leverage project management tools and best practices to improve visibility, efficiency, cross-functional alignment, and meeting effectiveness across GRSTs and project teams.
  • Experience facilitating cross-functional team meetings, driving structured agendas, documenting decisions and actions, and maintaining meeting hygiene and team accountability in a matrixed environment.
  • Expert skills in Smartsheet and Microsoft Office Suite.
  • Expertise creating visuals in PowerPoint using timeline integration tools such as One Pager and Office Timeline Pro.
  • Proficiency with Veeva Regulatory Information Management (RIM).
Responsibilities
  • Partner with Global Regulatory Leads to shape and execute globally aligned regulatory plans across product development and post-marketing.
  • Translate regulatory strategy into actionable plans with milestones, critical paths, risks, and opportunities to support planning and decision-making.
  • Lead regulatory plan execution, aligning daily operations with broader strategic objectives across global programs.
  • Identify and propose regulatory pathways and planning scenarios aligned with global regulatory expectations and business objectives.
  • Collaborate with cross-functional teams and senior leadership to drive clarity, alignment, and accountability for regulatory deliverables, timelines, and interdependencies.
  • Facilitate Global Regulatory Subteam (GRST) meetings and other project review forums, structuring meetings to support decision-making, risk mitigation, and regulatory execution.
  • Develop and distribute agendas, define objectives and discussion topics, maintain action logs, document decisions and next steps, track follow-up items to closure, and appropriately store and communicate meeting materials.
  • Maintain effective GRST governance, meeting cadence, stakeholder alignment, and communication flow across global and regional teams.
  • Anticipate and troubleshoot regulatory project and operational challenges, implementing solutions to strengthen team effectiveness, process efficiency, and submission readiness.
  • Prepare and deliver strategic dashboards, reports, and scenario plans to senior stakeholders, translating regulatory progress and risks into actionable business insights.
Desired Qualifications
  • An advanced degree (MS, PharmD, or PhD) and/or PMP certification is strongly preferred.
  • Experience supporting global development programs across multiple modalities or therapeutic areas is highly desirable.

About the company

T

Thermo Fisher Scientific

View

Thermo Fisher Scientific makes and sells the instruments, chemicals, consumables and lab services that drug companies, hospitals, universities and industrial labs use for research, testing and production. Its products cover work from gene sequencing and protein analysis to diagnostic tests and lab freezers, and its distribution arm ships supplies to labs worldwide. Drug developers also hire it to run clinical trials and to manufacture medicines under contract. It earns money from consumables that labs buy again and again, along with instrument sales, service contracts and outsourcing fees. The company traces its roots to Thermo Electron, founded in 1956, which merged with Fisher Scientific in 2006, and it is based in Waltham, Massachusetts.

Company Size

10,001+

Company Stage

IPO

Headquarters

Waltham, Massachusetts

Founded

1956

Get referred to Thermo Fisher Scientific

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Drugmaker demand is firming: revenue rose 10% to $11.99 billion in the June 2026 quarter, 5% excluding deals and currency.
  • Profits are outpacing sales, which supports stock grants: adjusted earnings per share rose 13% in the June 2026 quarter.
  • Career paths span many businesses: Thermo Fisher runs four segments, from diagnostics to contract drug development.

What critics are saying

  • Factory jobs are shrinking: Thermo Fisher announced in January 2026 it will close its Asheville plant, cutting 421 jobs.
  • Whole units get sold: microbiology, with $645 million in 2025 sales, went to buyout firm Astorg in August 2026.
  • Cuts reach California too: Thermo Fisher filed in January 2026 to lay off 173 Carlsbad workers by March.

What makes Thermo Fisher Scientific unique

  • Many familiar lab brands sit under one roof: Thermo Fisher owns Thermo Scientific, Applied Biosystems, Invitrogen and Fisher Scientific.
  • Thermo Fisher reaches labs through its own sales force of about 14,000 people, per its 2025 annual filing.
  • Its trial-data unit Clario has supported about 70% of FDA and EMA novel drug approvals over the past decade.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • Unlimited Paid Time Off
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Hybrid Work Options
  • 401(k) Retirement Plan
  • 401(k) Company Match

Company News

Yahoo Finance
Oct 29th, 2026
Thermo Fisher named a leader in cell and gene therapy CRO market after $12.1B Q3 sales

Thermo Fisher Scientific (NYSE:TMO) has been highlighted as a leading player in the cell and gene therapy contract research organisation (CRO) market. It offers integrated clinical trial services for advanced therapies as drugmakers outsource more R&D. Demand is tied to growing personalised medicine activity and stricter regulatory demands on complex trials. In its third-quarter 2026 report, the US life sciences group posted sales of $12.1 billion and net income of $1.7 billion. Basic earnings per share from continuing operations were $4.65. Investors are watching whether pharma and biotech services gain weight in Laboratory Products & Biopharma Services, and whether Clario adds revenue.

Yahoo Finance
Oct 29th, 2026
Thermo Fisher shares up 22.1% in 90 days as $12.1B quarterly sales leave stock 3% overvalued

Thermo Fisher Scientific (TMO) reported third quarter 2026 sales of $12.1 billion and net income of $1.7 billion. Its shares have gained 22.1% over 90 days and 18.8% so far this year. One-year total shareholder return stands at 26.6%. At a last close of $704.15, the stock trades about 3% above the $686.64 fair value set by the most followed narrative. Its price-to-earnings ratio of 36.8x compares with a fair ratio of 34.6x, a Global Life Sciences average of 38.1x, and a peer average of 40.1x. Risks include muted academic and government funding, and a longer drag on earnings from the microbiology divestiture.

Yahoo Finance
Oct 28th, 2026
Teen wins $25K for low-cost airborne bacteria sampler at Thermo Fisher Junior Innovators Challenge

Bailey Quinn Frank, 15, of Fort Lauderdale, Florida, won the $25,000 Thermo Fisher Scientific ASCEND Award, the top prize at the 2026 Thermo Fisher Scientific Junior Innovators Challenge. Thermo Fisher Scientific and Society for Science announced the winners in Washington, D.C. Frank built a low-cost environmental DNA sampler that uses a small fan and filter paper to collect airborne bacteria. She says it could help rural communities monitor health threats where resources for disease surveillance are limited. The 30 finalists, chosen from nearly 2,000 applicants, shared more than $100,000 in awards. Four other top winners each received $10,000, including twin brothers Henry and Jack Grover, 14, who developed a hydrogel sprayer to stop wildfires reigniting.

Yahoo Finance
Oct 23rd, 2026
Illumina stock is up 172.2% in a year, but is Thermo Fisher the cheaper buy?

Illumina and Thermo Fisher Scientific both sell to drug developers and patient-testing labs, but their financial profiles split evenly. Illumina stock returned 172.2% over the past year, against 21.7% for Thermo Fisher. Illumina raised its 2026 revenue forecast to a midpoint of $4.62 billion on July 30, driven by clinical markets. Thermo Fisher raised its 2026 guidance on October 21 to $47.7 billion–$48.2 billion, after third-quarter revenue rose 9% to $12.14 billion. Illumina leads on margins and debt: a 66.4% gross margin against 40.8%, and debt equal to 6.2% of market value against 17.0%. Thermo Fisher leads on price and growth. Illumina trades at 49.3 times trailing earnings, against 36.0 for Thermo Fisher, which also grew revenue 7.2% against 4.9%.

Yahoo Finance
Oct 22nd, 2026
Thermo Fisher Q3 revenue rises 9.1% to $12.14B, beating estimates on pharma and AI

Thermo Fisher beat Wall Street expectations in the third quarter of 2026, with sales up 9.1% year on year to $12.14 billion. Analysts had expected $11.96 billion. Adjusted earnings per share were $6.68, 4.3% above the $6.40 estimate. Operating margin rose to 18.6% from 17.5% a year earlier, and organic revenue grew 6%. Chief executive officer Marc Casper credited a broad recovery in end markets, high single-digit growth in pharma services, and strong electron microscopy demand from the semiconductor industry. Asia Pacific posted low double-digit growth. The company expects further momentum in pharma services and clinical research, and plans to integrate AI across its products. Bioscience reagents remain soft. Shares trade at $697.65, up from $687.37 before the results.